5M0B Stock Chart & Stats
€23.05
-€0.76(-4.50%)
At close: 4:00 PM EST
€23.05
-€0.76(-4.50%)
Day’s Range― - ―
52-Week Range€16.74 - €24.75
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€3.86B
Enterprise Value€50.31B
Total Cash (Recent Filing)€92.70M
Total Debt (Recent Filing)€1.46B
Price to Earnings (P/E)45.3
Beta0.67
Next Earnings
Nov 04, 2026EPS Estimate
0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.56
Shares Outstanding75,424,480
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)5.74
Price to Sales (P/S)1.29
P/FCF Ratio16.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.06
Revenue Forecast (FY)€228.02M
Bulls Say, Bears Say
Bulls Say
Organic Revenue GrowthDouble-digit organic growth across Healthcare and Diagnostics indicates broad demand and continued expansion of Medicover’s operating platform. Sustained volume growth can improve network utilization, deepen customer relationships, and support further earnings growth over the next several quarters.
Margin And ROIC ExpansionImproving EBIT margins and ROIC show that revenue growth is increasingly translating into more productive operations rather than only higher scale. Six consecutive quarters of margin improvement and acquisition synergies support the durability of current profitability gains.
Cash Generation And DeleveragingStrong operating cash flow, positive free cash flow, and falling leverage improve Medicover’s ability to fund expansion while servicing debt. Reaching sub-3x leverage also increases financial flexibility and supports management’s medium-term growth and investment targets.
Bears Say
Elevated LeverageAlthough leverage is improving, debt remains high relative to equity and reduces financial flexibility during a downturn or higher-rate environment. Elevated obligations may constrain discretionary investment, increase sensitivity to weaker cash generation, and limit room for unexpected pressures.
India Start-up LossesThe Indian hospital rollout is producing strong growth but currently weighs on consolidated margins while new facilities mature. Continued investment and ramp-up losses could delay profitability improvement, particularly if patient volumes or doctor recruitment develop more slowly than expected.
Reimbursement And Membership PressureMembership weakness and changing government-funded payment systems create structural uncertainty for revenue mix and profitability in affected markets. Tariff caps, budget changes, or wage-policy shifts could increase reliance on fee-for-service activity and make planning less predictable.
Medicover AB News
5M0B FAQ
What was Medicover AB’s price range in the past 12 months?
Medicover AB lowest stock price was €16.74 and its highest was €24.75 in the past 12 months.
What is Medicover AB’s market cap?
Medicover AB’s market cap is €3.86B.
When is Medicover AB’s upcoming earnings report date?
Medicover AB’s upcoming earnings report date is Nov 04, 2026 which is in 5 days.
How were Medicover AB’s earnings last quarter?
Medicover AB released its earnings results on Jul 22, 2026. The company reported €0.161 earnings per share for the quarter, missing the consensus estimate of €0.165 by -€0.004.
Is Medicover AB overvalued?
According to Wall Street analysts Medicover AB’s price is currently Overvalued.
Does Medicover AB pay dividends?
Medicover AB does not currently pay dividends.
What is Medicover AB’s EPS estimate?
Medicover AB’s EPS estimate is 0.17.
How many shares outstanding does Medicover AB have?
Medicover AB has 75,424,480 shares outstanding.
What happened to Medicover AB’s price movement after its last earnings report?
Medicover AB reported an EPS of €0.161 in its last earnings report, missing expectations of €0.165. Following the earnings report the stock price went down -0.706%.
Which hedge fund is a major shareholder of Medicover AB?
Currently, no hedge funds are holding shares in DE:5M0B
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Medicover AB
Established in 1995 and headquartered in Stockholm, Sweden, Medicover AB (publ) is a prominent international provider of both healthcare and diagnostic services. The company operates across numerous countries, including Germany, Sweden, Poland, Turkey, Belarus, Bulgaria, Georgia, Hungary, Serbia, Moldova, Ukraine, and India. It is structured into two main divisions: Healthcare Services and Diagnostic Services. Through its diagnostic division, Medicover performs a comprehensive array of specialized tests, which include analyses for allergy and autoimmune conditions; bacteriology and parasitology; biochemistry and immunochemistry; blood group diagnostics and transfusion medicine; tumour markers; clinical chemistry; cellular analyses like cytology, haematology, and histopathology; human genetics; hygiene; general immunology; infectious diseases; microbiology; molecular biology; and pharmacology/toxicology. Medicover maintains a substantial operational footprint, encompassing 97 clinical laboratories, 733 blood-drawing points, and 26 clinics dedicated to diagnostic services across 10 countries. Its healthcare segment further comprises 117 medical clinics, 20 fertility clinics, 52 dental clinics, 25 hospitals, and 25 gyms. The company caters to a broad customer base, serving corporate entities, private individuals, direct patients, and public sector payers.